Antihypertensive Drugs: 2025 AHA/ACC Guideline, Mechanisms and Safe Treatment

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling.

Overview

Hypertension increases the risk of stroke, myocardial infarction, heart failure, kidney disease and premature death. The 2025 AHA/ACC guideline emphasizes repeated accurate blood pressure assessment, lifestyle interventions and individualized drug treatment. Home readings improve monitoring, but confirmation of diagnosis and thresholds depend on clinical circumstances [1, 2].

Drug classes and mechanisms

  • ACE inhibitors: lisinopril, enalapril reduce angiotensin II and increase bradykinin; ARBs: losartan, valsartan block AT1 receptors.
  • Thiazide/thiazide-like diuretics: hydrochlorothiazide, chlorthalidone, indapamide reduce distal sodium reabsorption.
  • Dihydropyridine calcium-channel blockers: amlodipine, nifedipine lower peripheral arteriolar resistance.
  • Non-dihydropyridine calcium-channel blockers: verapamil, diltiazem reduce heart rate and AV conduction.
  • Beta blockers: metoprolol, bisoprolol selectively inhibit beta-1 receptors; carvedilol and labetalol have combined beta- and alpha-1-blocking properties. Carvedilol is not a thiazolidinedione.
  • Mineralocorticoid receptor antagonists: spironolactone/epleronone block aldosterone effects, especially useful in selected resistant hypertension and HFrEF.
  • Other: loop diuretics, alpha blockers, clonidine, hydralazine/minoxidil and direct renin inhibition are selected according to specific indications [1].

When to start medication

The 2025 US guideline recommends medication alongside lifestyle measures for adults with an average systolic pressure of at least 140 mm Hg or diastolic pressure of at least 90 mm Hg. At 130/80 mm Hg or higher, clinical cardiovascular disease, previous stroke, diabetes, chronic kidney disease or a 10-year PREVENT cardiovascular risk of at least 7.5% supports starting medication. For lower-risk adults with persistent readings at or above 130/80 after three to six months of lifestyle measures, medication is also recommended. These thresholds apply to the US adult pathway. The general treatment goal is below 130/80 mm Hg, individualised for frailty, symptoms and clinical circumstances. [2]

Combination and comorbidity-based selection

ACEi/ARB, thiazide-type diuretics and long-acting dihydropyridine CCBs are common first-line choices; stage 2 disease often warrants a two-drug combination from distinct classes. ACEi or ARB may be particularly helpful in albuminuric kidney disease; HFrEF benefits from evidence-based beta blockers and renin–angiotensin system therapy as part of disease-modifying care. Beta blockers are not usually initial monotherapy solely for uncomplicated hypertension without a compelling indication [1, 2].

Interactions and adverse effects

ACE inhibitors can cause cough, hyperkalemia, renal dysfunction and rare angioedema. ARBs also affect potassium/kidney function but usually cause less cough. Thiazide drugs may cause hyponatremia, hypokalemia and hyperuricemia; dihydropyridine CCBs can cause ankle edema. Beta blockers may cause bradycardia and mask hypoglycemia warning signs. Non-dihydropyridine CCBs can worsen systolic HF. Avoid combining ACE inhibitors with ARBs routinely, and avoid ACEi/ARB/direct renin inhibitors during pregnancy [1].

Hypertension in pregnancy

Pregnancy has its own treatment thresholds and drug choices. Review ACE inhibitors and ARBs when pregnancy is planned and stop them promptly if pregnancy occurs, with an appropriate alternative. NICE advises considering labetalol for chronic hypertension in pregnancy, then nifedipine if labetalol is unsuitable, and methyldopa if both are unsuitable. [3]

Monitoring and safety

Obtain appropriate renal function, electrolyte and cardiovascular assessment at baseline and following titration; use home BP logs and review orthostatic symptoms, adherence, costs and medication technique. Severe BP elevation with acute end-organ damage is a hypertensive emergency requiring monitored IV treatment, not routine outpatient oral dose escalation [1, 2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC guideline for prevention, detection, evaluation and management of high blood pressure in adults. Hypertension. 2025;82:e212–e316. doi:10.1161/HYP.0000000000000249. Available from: https://doi.org/10.1161/HYP.0000000000000249
  3. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. Guideline NG133. View source.
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *